Table 3

Variables at baseline, pre-propensity and post-propensity score matching for patients with ≥1 year of follow-up from pooled LTE and Toronto Lupus Cohort datasets

VariablePre-propensity score matching
(n=1541)
Post-propensity score matching
(n=646)
Mean% BiasMean% Bias
BelimumabStandard therapyBelimumabStandard therapy
Age38.78236.73516.238.10837.4165.4
 Age squared1634.01538.59.01611.11566.94.2
Female0.9420.88520.40.9260.9134.5
Race
 Black0.0750.150−24.10.1150.1082.0
 Asian/other0.4570.30132.70.3370.362−5.2
SLE duration6.7376.3585.57.0616.8033.6
Hypertension0.4000.3833.30.4120.4021.9
Dyslipidaemia0.1280.471−80.70.2790.282−0.7
Proteinuria0.1690.346−41.30.2450.263−4.3
ACR criteria5.9715.67421.65.9015.8920.7
Baseline SLEDAI8.27310.100−39.89.1059.0461.4
Corticosteroid use0.8590.63952.50.7150.743−6.3
Antimalarial use0.6690.59315.80.6560.6285.8
Immunosuppressive use0.4720.37220.40.3990.409−1.9
Baseline SDI=10.2410.15022.90.2350.1959.8
Baseline SDI≥20.1770.10321.30.1330.139−1.8
  • ACR, American College of Rheumatology; LTE, long-term extension; SDI, SLICC/ACR Damage Index; SLE, systemic lupus erythematosus;; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SLICC, Systemic Lupus International Collaborating Clinics.